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Abstract
Background
Currently in Japan, both 23-valent pneumococcal polysaccharide vaccine (PPSV–23) and
13-valent pneumococcal conjugate vaccine (PCV–13) are available for the elderly for the
prevention of S. pneumoniae-related diseases. PPSV–23 was approved in 1988, while the
extended use of PCV–13 was approved for adults aged 65 and older in June 2014. Despite
these two vaccines being available, the recently launched national immunisation pro-
gramme for the elderly only subsidised PPSV–23. The framework of the current immunisa-
tion programme lasts for five years. The elderly population eligible for the subsidised
PPSV–23 shot for the 1st year are those aged 65, 70, 75, 80, 85, 90, 95 and100. While
from the 2nd year to the 5th year, those who will age 65, 70, 75, 80, 85, 90, 95 and 100 will
receive the same subsidised shot.
Methods
We performed economic evaluations to (1) evaluate the efficiency of alternative strategies
of PPSV–23 single-dose immunisation programme, and (2) investigate the efficiency of
PCV–13 inclusion in the list for single-dose pneumococcal vaccine immunisation pro-
gramme. Three alternative strategies were created in this study, namely: (1) current PPSV–
23 strategy, (2) 65 to 80 (as “65–80 PPSV–23 strategy”), and (3) 65 and older (as “65
PPSV–23 strategy”). We constructed a Markov model depicting the S. pneumoniae-related
disease course pathways. The transition probabilities, utility weights to estimate quality
adjusted life year (QALY) and disease treatment costs were either calculated or cited from
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literature. Cost of per shot of vaccine was ¥8,116 (US$74; US$1 = ¥110) for PPSV–23 and
¥10,776 (US$98) for PCV–13. The model runs for 15 years with one year cycle after immu-
nisation. Discounting was at 3%.
Results
Compared to current PPSV–23 strategy, 65–80 PPSV–23 strategy cost less but gained
less, while the incremental cost-effectiveness ratios (ICERs) of65 PPSV–23 strategy was
¥5,025,000 (US$45,682) per QALY gained. PCV–13 inclusion into the list for single-dose
subsidy has an ICER of ¥377,000 (US$3,427) per QALY gained regardless of the PCV–13
diffusion level. These ICERs were found to be cost-effective since they are lower than the
suggested criterion by WHO of three times GDP (¥11,000,000 or US$113,636 per QALY
gained), which is the benchmark used in judging the cost-effectiveness of an immunisation
programmne.
Conclusions
The results suggest that switching current PPSV–23 strategy to65 PPSV–23 strategy or
including PCV–13 into the list for single-dose subsidy to the elderly in Japan has value for
money.
Introduction
23-valent pneumococcal polysaccharide vaccine (PPSV–23) has been recommended for pre-
vention of invasive pneumococcal disease (IPD) in adults since 1983 [1]. It was the only pneu-
mococcal vaccine available for all adults aged 65 and older until the approval of the extended
use of 13-valent pneumococcal conjugate vaccine (PCV–13) for prevention of pneumococcal
pneumonia and IPD in adults 50 years and older on December 30, 2011 by US Food and Drug
Administration [1]. On August 13, 2014, the Advisory Committee on Immunization Practices
of US Centers for Disease Control and Prevention modified the recommendation on pneumo-
coccal vaccine for the elderly. The new recommendation states that “Both PCV13 and PPSV23
should be routinely administered in series to all adults aged65 years”, which is based on the
results of a randomised placebo-controlled trial showing PCV–13 efficacy against community-
acquired pneumonia (CAP) among approximately 85,000 adults aged 65 and older [1]. PPSV–
23 and PCV–13 differ in cost, number of serotypes covered, mechanism for immunogenicity,
and level of effectiveness, particularly against non-bacteremic pneumococcal pneumonia
(NPP).
Currently, in Japan, both PPSV–23 and PCV–13 are available for the elderly for the preven-
tion of S. pneumoniae-related diseases. PPSV–23 was approved in 1988 [2]. However, only
some municipalities coordinated publicly-funded pneumococcal immunisation programmes
for the elderly from 2001 through September 2014; vaccine coverage was about 25% [3]. On
the other hand, the extended use of PCV–13 in adults aged 65 and older was approved in June
2014. Despite of these two vaccines being available for elderly, the national immunisation pro-
gramme launched for the elderly aged 65 and older on October 1, 2014 only subsidised PPSV–
23. The framework of the current immunisation program lasts for five years. The elderly popu-
lation eligible for the subsidised PPSV–23 shot for the 1st year are those aged 65, 70, 75, 80, 85,
90, 95 and100. While from the 2nd year to the 5th year, those who will age 65, 70, 75, 80, 85,
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90, 95 and 100 will receive the same subsidised shot [4]. Countries, where publicly funded
PPSV–23 immunisation programmes for elderly have been launched, set the eligible age to
receive a shot of subsidised vaccine as 65 to 80, 65 and older, 70 and older, and so on [1, 5–9].
Due to the limited resources for health care, there is a need to organize an efficient immunisa-
tion programme. This study builds upon such need and intends to address such issues by (1)
evaluating the efficiency of alternative strategies of PPSV–23 immunisation programmes, and
(2) investigating the efficiency of PCV–13 inclusion in the list of single-dose pneumococcal
vaccine national immunisation programme.
Methods
We conducted a cost-effectiveness analysis with Markov modelling from payers’ perspective.
We conducted a literature survey to define the alternative immunisation programmes and to
construct the model. Studies pertaining to epidemiology and prognosis of relevant diseases
caused by S. pneumoniae in Japan’s setting were accessed from PubMed database, Igaku Chuo
Zasshi (Japana Centra Revuo Medicina) database, Ministry of Health, Labour and Welfare
(MHLW) Grant System, and annual statistic reports published by the government. Igaku Chuo
Zasshi, a Japanese medical bibliographic database, which contains over 10 million citations
originating from Japan, comprehensively covers articles published in Japanese-language medi-
cal journals. Due to insufficient evidences from Japan, overseas’ reports from PubMed, Med-
line, The Cochrane Database of Systematic Reviews, Health Technology Assessment database,
and The NHS Economic Evaluation Database regarding vaccine effectiveness, utility weights to
estimate quality adjusted life year (QALY) and economic evaluation related to vaccines were
used instead.
PPSV–23 programmes and inclusion of PCV–13
The target population of the immunisation programmes to be evaluated are those aged 65 and
older in 2014. In evaluating the efficiency of different PPSV–23 immunisation programmes, we
set three different strategies with different ages to receive a shot of subsidised vaccine, namely:
(1) current PPSV–23 strategy, (2) 65 to 80 (as “65–80 PPSV–23 strategy”), and (3) 65 and older
(as “65 PPSV–23 strategy”). Age-specific populations were from demographic data [10]. Cur-
rent PPSV–23 strategy served as a comparator of the other two strategies. In 65–80 PPSV–23
strategy, those who aged over 80 were not eligible to the immunisation programme, which
means these individuals will only follow the transition probabilities assigned to the correspond-
ing ages without any vaccine effectiveness on reducing any S. pneumoniae-related diseases.
Vaccine uptake rates were assumed at 50.4% for all strategies, which was the same with the cov-
erage rate of seasonal influenza vaccine in 2013 [11].
In order to investigate the cost-effectiveness of PCV–13 inclusion in the list for single-dose
pneumococcal vaccine national immunisation programme, we made variations on the share of
PCV–13 between the two pneumococcal vaccines from 10% to 100% with 10% interval,
because it is unknown how doctors, vaccinees, and municipalities will choose between PPSV–
23 and PCV–13. Ten levels of diffusion of PCV–13 were compared with current PPSV–23
strategy.
Only single-dose subsidy was analysed and not the sequence of PCV–13/PPSV–23 or
PPSV–23/PCV–13, this is mainly due to PPSV–23 immunisation being a newly-launched pro-
gramme in Japan [12, 13]. We reserve the evaluation of the cost-effectiveness of uptaking the
two vaccines in the future research so as to delineate and emphasize on the main purpose of
the study.
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Markov model
AMarkov model of courses followed by the cohort under consideration was constructed based
on epidemiological data, vaccine effectiveness and models from previous studies. Seven mutu-
ally-exclusive health states were modelled: health (without any S. pneumoniae-related diseases),
bacteremia without pneumococcal pneumonia, bacteremia with pneumococcal pneumonia,
meningitis, CAP caused by S. pneumoniae, neurological sequelae and death of or other than
the related diseases (Fig 1). A Markov cycle for each stage was set at one year with a cohort
timeframe of 15 years after being vaccinated. We assumed all the individuals who survived
until the timeframe age have a life expectancy of the Japanese population [14]. Adverse effects
associated with vaccination of PPSV–23 and PCV–13 were not considered, since they were
mild or moderate in severity [15–17]. Considering that all transition states did not occur simul-
taneously at the end of each cycle, while in reality, most kinds of transitions typically occur
gradually throughout a time interval (on average, half-way through), we implemented a half-
cycle correction in estimating the incremental cost-effectiveness ratios (ICERs) of the pro-
grammes [18]. The half-cycle correction is implemented by using one-half of every state’s
incremental reward in model’s initial and final reward.
Fig 1. Markov Model.
doi:10.1371/journal.pone.0139140.g001
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Outcomes estimation
Outcomes in terms of QALY were estimated by assigning transition probabilities and utility
weights from literature. We estimated the 5-year age-specific incidence rates using the follow-
ing: (1) annual IPD incidence rates among persons age 65 and over (2.41 per 100,000) [19], (2)
IPD distribution by age [19], and (3) demographic data [10]. NPP annual incidence rates were
estimated as incidence of CAP times proportion of S. pneumonia-caused CAP at 17.2% [20].
CAP incidence rates, 10.7 and 42.9 per 1000 person-years for persons who were aged 65–74
and aged75, respectively, were from a 3-year prospective hospital-based surveillance [21].
Proportions of bacteremia with/without pneumococcal pneumonia, and meningitis among
IPD cases were from the Infectious Agents Surveillance Report (IASR) [19]. Ubukata’s results
of IPD case-fatality rates and proportion that results in neurological sequelae among IPD cases
and NPP cases were used in the study [22]. NPP case-fatality rate was from Ishida et al.’s study,
which reported the rate among patients with positive urinary antigen test of S. pneumoniae-
related pneumonia [23]. Deaths of causes other than the above diseases were taken from the
vital statistics [24]. Utility weights used to calculate QALY were assumed based on a study by
Smith et al. [25]. Average lengths of hospital stay were from published government data [26].
All these data are shown in Table 1.
Vaccine effectiveness of PPSV–23 in reducing IPD incidence rate was cited from a Cochrane
Review report [30]. Results from meta-analysis show that the use of PPSV–23 to prevent vac-
cine serotype IPD in adults of high-income countries, was at 82% (69%-90%), while its effec-
tiveness in reducing non-IPD was inconsistent. We assumed that the effectiveness in reducing
non-IPD to be 0% [30]. PCV–13 effectiveness in reducing vaccine-serotype IPD and non-inva-
sive vaccine-type CAP, 75.0% and 45.0%, respectively, were from a randomised placebo-con-
trolled trial study [31]. We assumed the effectiveness of both vaccines reduce by age of
vaccination and by years after being vaccinated. Extent of reduction was proportional to the
effectiveness used in Smith et al.’s study [25]. All these data are shown in Table 2. The vaccine
serotypes causing IPD among elderly were 60.0% and 46.0% for PPSV–23 and PCV–13 [19],
respectively, those for NPP were 62.7% and 49.3% [13] (Table 1).
Costing
In this study, costs borne by government, municipalities, vaccinees, patients and third party
payers were considered, while advertising costs borne by manufacturers were left unaccounted.
It is obvious that when a new product enters a market, which was monopolised by the other
product, the manufacturers of both products will invest a lot to compete for the share in the
market. Since the decision maker, MHLW Vaccine Committee, was only interested in costs
borne by the aforementioned payers, we omitted the inclusion of this cost. Non-direct medical
costs related to the immunisation programme were not included, because the programme was
built within the public health services routine [32]. The amount of direct payments to health
care providers by these entities was estimated as costs. Cost items were identified along the
decision tree and Markov model. We used the literature along with some assumptions to esti-
mate necessary data.
Age-specific treatment costs of per case of bacteremia with/without pneumococcal pneumo-
nia and pneumonia were estimated from Status Survey on Medical Care Benefits [26]. Cost per
case of meningitis was assumed to be twice the cost per case of bacteremia, while cost of
sequelae was assumed ¥1,500,000 (US$13,636) per case per year [27]. One vaccine shot was
assumed at ¥8,116 (US$ 74: US$1 = ¥110) for PPSV–23 and ¥10,776 (US$98) for PCV–13,
which were the sum of vaccine price (¥4,737 or US$43 for PPSV–23, ¥7,200 or US$65 for
CEA of Pneumococcal Vaccines Immunisation Programme for the Elderly
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Table 1. Model inputs.
Distribution of population among adults aged 65 and older
Age % [10]
65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 6.9, 6.6, 4.1, 4.4, 5.3, 5.1, 5.2, 5.0, 4.5, 3.9,
75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 4.1, 4.2, 4.1, 3.8, 3.5, 3.4, 3.2, 3.0, 2.7, 2.5,
85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 2.3, 2.1, 1.9, 1.6, 1.3, 1.1, 0.9, 0.7, 0.6, 0.4,
95, 96, 97, 98, 99,100+ 0.3, 0.3, 0.2, 0.1, 0.1, 0.2
Percentage of female among each age
51.4, 51.5, 51.9, 52.4,52.7, 52.9,53.2, 53.4, 53.8, 54.2,
54.8, 55.3,55.9,56.7,57.6, 58.6, 59.3, 60.4,61.5,62.8
63.9, 65.4, 66.9, 69.2, 71.2 74.4, 76.3, 77.7, 78.4, 79.9
81.1, 81.6, 83.6,84.1,84.8, 87.3
Rate and proportionsa 65+ 65–69 70–74 75–79 80–84 85–89 90–94 95+
Annual incidence rate of IPD (per 100,000 population) 2.4 1.8 1.8 2.5 2.7 4.2 4.4 4.2 [10,
19]
Bacteremia without pneumococcal pneumonia among IPD
cases (%)
35.6 36.8 40.0 29.8 38.0 33.9 42.1 16.7 [19]
Bacteremia with pneumococcal pneumonia among IPD
cases (%)
45.8 39.5 35.5 50.7 45.1 54.8 50.0 66.7 [18]
Meningitis among IPD cases (%) 18.6 23.6 24.5 19.6 16.8 11.3 7.9 16.7 [19]
Annual incidence rate of CAP (per 1,000 population) 10.7 (aged 65–74), 42.9 (age > = 75) [21]
CAP caused by S. pneumoniae (%) 17.2 [20]
Bacteremia without pneumococcal pneumonia result in
sequelae (%)
2.0 [22]
Bacteremia with pneumococcal pneumonia result in
sequelae (%)
7.0 [22]
Meningitis result in sequelae (%) 30.0 [22]
Non-bacteremic pneumococcal pneumonia result in
sequelae (%)
2.7 [22]
Case-fatality rate (%)
Bacteremia without pneumococcal pneumonia 25.0 [22]
Bacteremia with pneumococcal pneumonia 30.5 [22]
Meningitis 14.9 [22]
Non-bacteremic pneumococcal pneumonia 1.9 [23]
Sequelae 5.0 [22]
Serotypes covering of disease caused by S. pneumococcus
Invasive pneumococcal diseases PPSV–23: 60.0% PCV–13: 46.0% [19]
Non-bacteremic pneumococcal pneumonia PPSV–23: 62.9% PCV–13: 49.3% [13]
Utility weights [25]
Health 1
Bacteremia without pneumococcal pneumonia 0.5
Bacteremia with pneumococcal pneumonia 0.5
Meningitis 0.4
Pneumococcal pneumonia 0.5
Sequelae 0.3
Death 0
Average lengths of hospital stay (day) 65–69 70–74 75–79 80–84 85–89 90–94 95–99 100+
Bacteremia/pneumonia 12.3 13.1 14.1 14.9 15.6 16.1 16.3 16.2 [26]
Meningitis 24.5 26.3 28.3 29.9 31.2 32.1 32.6 32.4 [26]
Treatment costs per case (¥)
(Continued)
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PCV–13) [28, 29], doctor fee and technical fee for PPSV–23 and PCV–13, respectively. All cost
data are shown in Table 1.
Discounting
Outcomes and costs were discounted at a rate of 3% [32].
One-way sensitivity analyses and probabilistic analyses
We performed one-way sensitivity analyses on two pairs of comparisons. The first pair is65
PPSV–23 strategy vs. current PPSV–23 strategy, which is to appraise the stability of ICERs
with the assumptions made in our economic model, and to explore the impact of each variable
relative to each other when the subsidy of the immunisation is limited to PPSV–23. The second
pair is PCV–13 strategy vs. current PPSV–23 strategy, which is to appraise the same issues
when PCV–13 is also subsidised by current immunisation programme. The lower limits and
upper limits used in sensitivity analyses were ±50% for costs variables and ±20% for probabili-
ties and utilities. We also conducted two sets of 1000 Monte Carlo simulations on65 PPSV–
23 strategy and 65–80 PPSV–23 strategy vs. current PPSV–23 strategy, i.e., probabilistic analy-
ses, for which all data were assumed to have an equilateral triangle distribution corresponding
to the range tested in one way sensitivity analyses. Triangular distribution was used because of
the insufficiency of information about distributions. This distribution has been theoretically
proven as both simple and efficient, which can serve as a proxy for beta or other distributions
in risk analysis [33–35].
Results
Costs, effectiveness, and cost-effectiveness of alternative PPSV–23
single-dose immunisation strategies
Compared to current PPSV–23 strategy, the incremental cost and incremental effectiveness
per person for65 PPSV–23 strategy were ¥216 (US$2) and 0.00004 QALYs; estimated ICER
Table 1. (Continued)
Distribution of population among adults aged 65 and older
Bacteremia/pneumonia 428,005 440,028 453,172 453,404 449,147 435,079 425,829 408,372 [26]
Meningitis 856,011 880,057 906,343 906,808 898,293 870,158 851,658 816,744 [26]
Sequelae (per case per year) 1,500,000 [27]
Costs per vaccination (¥)
Cost per PPSV–23 shot 8,116 [28,
29]
Cost per PCV–13 shot 10,776 [28,
29]
aOn Markov model, transition probabilities from health state A to health state B by ages were calculated as follows
From “Health” to “Bacteremia without pneumococcal pneumonia” = Annual incidence rate of IPD × Bacteremia without pneumococcal pneumonia among
IPD cases
From “Health” to “Bacteremia with pneumococcal pneumonia” = Annual incidence rate of IPD × Bacteremia with pneumococcal pneumonia among IPD
cases
From “Health” to “Meningitis” = Annual incidence rate of IPD × Meningitis among IPD cases
From “Health” to “Non-bacteremic pneumococcal pneumonia” = Annual incidence rate of CAP × CAP caused by S. pneumoniae
doi:10.1371/journal.pone.0139140.t001
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was ¥5,025,000 (US$45,682) per QALY gained. For 65–80 PPSV–23 strategy, incremental cost
and incremental effectiveness were both negative values, which indicated that 60–80 PPSV–23
strategy cost less but also gained less than current PPSV–23 strategy (Table 3).
Costs, effectiveness, and cost-effectiveness of including PCV–13 in the
list of single-dose subsidy
Among 10 scenarios with different PCV–13 diffusion levels, scenarios with higher PCV–13 dif-
fusion level resulted in larger vaccine cost, while it saved more treatment costs and gained
more QALYs compared to current scenario. Reduced treatment costs did not offset vaccination
Table 2. Data used to estimate vaccine effectiveness (VE) and VEs used in the model.
Data used to estimate vaccine effectiveness (1–3)
1. Vaccine effectiveness of PPSV–23 and PCV–13 in preventing IPD used in Smith et. al's study [25] (%)
PPSV–23 PCV–13
years post aged 65–79 aged 80 and over aged 65 and over
vaccination base-case low high base-case low high base-case low high
1 80.0 60.0 90.0 67.0 20.0 85.0 85.0 60.0 95.0
3 73.0 50.0 83.0 53.0 0 83.5 80.0 45.0 90.0
5 58.0 30.5 80.0 32.0 0 75.0 70.0 30.0 87.0
7 33.0 13.0 48.0 10.0 0 30.0 60.0 22.5 77.5
10 0 0 10.0 0 0 10.0 50.0 15.0 68.0
15 0 0 10.0 0 0 10.0 33.0 0 60.0
2. Vaccine effectiveness of PPSV–23 in preventing vaccine type IPD (in high income countries) (%)
(based on Cochrane database of systemic review [30])
82 69 90
3. Vaccine effectiveness of PCV–13 in preventing IPD and non-bacteremic CAP based on CApiTA study [31]) (%)
Reduced non-bacteremic vaccine type CAP 45.0
Reduced vaccine-type IPD 75.0
VE in preventing IPD used in current study (%) (Based on 1, 2, and 3)
PPSV–23 PCV–13
years post aged 65–79 aged 80 and over aged 65–79 aged 80 and over
vaccination base-case low high base-case low high base-case low high base-case low high
1 82.0 69.0 90.0 68.7 23.0 85.0 75.0 52.9 83.8 62.8 17.6 79.2
3 74.8 57.5 83.0 54.3 0.0 83.5 70.6 39.7 79.4 51.2 13.2 75.0
5 59.5 35.1 80.0 32.8 0.0 75.0 61.8 26.5 76.8 34.1 8.8 72.5
7 33.8 15.0 48.0 10.3 0.0 30.0 52.9 19.9 68.4 16.0 6.6 64.6
10 0 0 10.0 0 0 10.0 44.1 13.2 60.0 0 0 56.7
15 0 0 10.0 0 0 10.0 29.1 0 52.9 0 0 50.0
VE in preventing non-invasive vaccine type CAP used in current study (%) (Based on 1, 2, and 3)
PPSV–23 PCV–13
years post aged 65–79 aged 80 and over aged 65–79 aged 80 and over
vaccination base-case low high base-case low high base-case low high base-case low high
1 - - - - - - 45.0 31.8 50.3 37.7 26.6 42.1
3 - - - - - - 42.4 23.8 47.6 30.7 17.3 34.6
5 - - - - - - 37.1 15.9 46.1 20.4 8.8 25.4
7 - - - - - - 31.8 11.9 41.0 9.6 3.6 12.4
10 - - - - - - 26.5 7.9 36.0 0 0 0
15 - - - - - - 17.5 0 31.8 0 0 0
doi:10.1371/journal.pone.0139140.t002
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cost, which means gained more QALYs with more costs. ICERs were ¥378,000 (US$3,436) per
QALY gained regardless of PCV–13 diffusion level (Table 4).
Results of one-way sensitivity analyses and probabilistic analyses
In one-way sensitivity analyses of65 PPSV–23 strategy vs. current PPSV–23 strategy, the var-
iables which were found to increase/decrease ICER more than ¥1,000,000 (US$9,091) are as
follows: (1) cost of per vaccine shot, (2) IPD incidence rate, (3) vaccine effectiveness of PPSV–
23 in reducing IPD incidence rate, and (4) percentage of vaccine serotype causing IPD (Fig
2A). In PCV–13 strategy vs. current PPSV–23 strategy, only costs per shot of PCV–13 and per
shot of PPSV–23 were found to produce large changes in ICERs (Fig 2B). Figs 3 and 4 show the
results of probabilistic analyses. Each dot on Fig 3 represents the incremental cost and effect
obtained from one simulation following the random draw of model parameters from distribu-
tion. The cost-effectiveness acceptability curve (CEAC) shows that in65 PPSV–23 strategy
vs. current PPSV–23 strategy, among 1000 ICERs produced by Monte Carlo simulations,
61.5% are under ¥5,500,000 (US$50,000) per QALY and 100% are under ¥10,000,000 (US
$90,910) per QALY (Fig 4).
Table 3. Cost, effectiveness and incremental cost-effectiveness ratio (vs. current scenario) by using PPSV–23 only.
Vaccine cost
per person
Treatment cost
per person
Total cost per
person
Effectiveness per
person
Incremental
cost
Incremental
effectiveness
ICER*
= (5)/(6)
¥ ¥ ¥ QALY ¥ QALY
(1) (2) (3) = (1)+(2) (4) (5) (6)
Current
strategy
3,860 20,456 24,316 14.31480 - - -
65–80
strategy
2,259 20,460 22,719 14.31480 -1,597 -0.00001 cost less,
gain less
65
strategy
4,091 20,441 24,532 14.31485 216 0.00004 5025,000
*ICER: incremental cost-effectiveness ratio (¥/QALY gained). All ICERs were rounded to the nearest thousand.
doi:10.1371/journal.pone.0139140.t003
Table 4. Cost, effectiveness and incremental cost-effectiveness ratio of different diffusion levels of PCV–13 (vs. current PPSV–23 strategy).
Diffusion level of
PCV13 vs. PPSV–23
Vaccine cost
per person
Treatment cost
per person
Total cost
per person
Effectiveness per
person
Incremental
cost
Incremental
effectiveness
ICER*
= (5)/(6)
¥ ¥ ¥ QALY ¥ QALY
(1) (2) (3) = (1)+(2) (4) (5) (6)
0% vs. 100% (Current
strategy)
3,860 20,456 24,316 14.31480 - - -
10% vs. 90% 3,987 20,350 24,337 14.31486 21 0.00006 378,000
20% vs. 80% 4,113 20,245 24,358 14.31491 42 0.00011 378,000
30% vs. 70% 4,240 20,140 24,380 14.31497 64 0.00017 378,000
40% vs. 60% 4,366 20,035 24,401 14.31503 85 0.00022 378,000
50% vs. 50% 4,493 19,929 24,422 14.31508 106 0.00028 378,000
60% vs. 40% 4,619 19,824 24,443 14.31514 127 0.00034 378,000
70% vs. 30% 4,746 19,719 24,464 14.31520 149 0.00039 378,000
80% vs. 20% 4,872 19,613 24,486 14.31525 170 0.00045 378,000
90% vs. 10% 4,999 19,508 24,507 14.31531 191 0.00051 378,000
*ICER: incremental cost-effectiveness ratio (¥/QALY gained). All ICERs were rounded to the nearest thousand.
doi:10.1371/journal.pone.0139140.t004
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Fig 2. Results of one-way sensitivity analyses. (A)65 PPSV–23 strategy vs. current PPSV–23 strategy. (B) PCV–13 strategy vs. current PPSV–23
strategy. In Fig 2A: (1) Cost per shot of PPSV–23, (2) Annual incidence rate of IPD, (3) Vaccine effectiveness of PPSV–23 in reducing IPD incidence rate, (4)
Percentage of vaccine serotype causing IPD. In Fig 2-B: (1) Cost per shot of PCV–13. (2) Cost per shot of PPSV–23, (3) Vaccine effectiveness of PCV–13 in
preventing noninvasive vaccine type CAP, (4) Treatment cost per S. pneumoniae-related case.
doi:10.1371/journal.pone.0139140.g002
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Discussion
This study intends to address the following objectives: (1) to evaluate the efficiency of alterna-
tive PPSV–23 immunisation strategies compared to current PPSV–23 strategy, and (2) to
investigate the cost-effectiveness of the inclusion of PCV–13 in the list of single-dose current
pneumococcal vaccine national immunisation programme.
Compared to the current PPSV–23 strategy, incremental cost and incremental effectiveness
of 65–80 PPSV–23 strategy were both negative, which means that switching current strategy to
65–80 strategy was found to gain less QALYs than current PPSV–23 strategy (this outcome
will not be considered in decision-making). Switching current PPSV–23 strategy to65
PPSV–23 strategy was found to be favourable (ICER at ¥5,025,000 or US$45,682 per QALY
gained) compared to either of the suggested criterion by WHO of three times GDP (around
¥11,000,000 or US$113,636 per QALY gained in Japan) [36], or by Shiroiwa at ¥5,000,000 (US
$45,455) per QALY gained [37]. Moreover, the result of probabilistic sensitivity analyses on
switching current PPSV–23 strategy to65 PPSV–23 strategy, ICER to be under ¥5,500,000
(US$50,000) per QALY is 61.5% and is 100% to be under ¥10,000,000 (US$90,910) per QALY
gained, is deemed to be cost-effective.
Fig 3. Results of probabilistic sensitivity analyses. (A) Scatter plot of incremental cost and incremental effectiveness per person of65 PPSV–23
strategy vs. current PPSV–23 strategy and 65–80 PPSV–23 strategy vs. current PPSV–23 strategy. (B) Enlarged view of65 PPSV–23 strategy vs. current
PPSV–23 strategy. (C) Enlarged view of 65–80 PPSV–23 strategy vs. current PPSV–23 strategy.
doi:10.1371/journal.pone.0139140.g003
CEA of Pneumococcal Vaccines Immunisation Programme for the Elderly
PLOS ONE | DOI:10.1371/journal.pone.0139140 October 7, 2015 11 / 16
We compared 10 scenarios (with 10 PCV–13 diffusion levels) to current PPSV–23 strategy.
Results showed that PCV–13 inclusion in the subsidy list has value for money (ICER =
¥378,000 or US$3,436 per QALY gained, regardless of PCV–13 diffusion level).
Since there are only a few variables which will induce the ICER to go beyond ¥1,000,000
(US$9,091) per QALY gained, we consider our results to be robust. In comparing65 PPSV23
strategy with current PPSV23 strategy, the top four variables which have the biggest impact on
ICER were cost per vaccine shot, IPD incidence rate, vaccine effectiveness, and percentage of
vaccine serotype causing IPD. On the other hand, in comparing PCV–13 strategy with current
PPSV–23, only cost per vaccine shot will change the ICER larger than ¥1,000,000 (US$9,091)
per QALY.
This study has several limitations. In Japan, before the national immunisation programme
was launched, some municipalities already provided subsidies to the elderly for single shot
PPSV–23 from 2001 to September 2014 with a vaccine coverage of about 25% [3]. We didn’t
incorporate the already-vaccinated group in our model since the efficiencies of the pro-
grammes were determined by incremental difference of costs and QALYs between the
Fig 4. Cost-effectiveness acceptability curve (CEAC) of65 PPSV–23 strategy vs. current PPSV–23 strategy.
doi:10.1371/journal.pone.0139140.g004
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comparator and alternatives; its influence to the results should be limited. Due to insufficient
data of the municipality-led PPSV–23 immunisation programmes for the elderly, we decided
not incorporate this into the model. Considering that more elderly will uptake vaccine through
these extra programmes, the strategy will move from current PPSV–23 strategy towards 65
PPSV–23 strategy and these results will be useful for those municipalities. We assumed that in
both 65–80 PPSV–23 strategy and 65 PPSV–23 strategy, the eligible persons will uptake vac-
cine in the first year. Since the incidence rates of pneumococcal diseases and the vaccine effec-
tiveness varies with age, it was difficult to predict how the results will change. Based on
previous study [38], if an eligible person uptakes vaccine around 70–75 years old, it would
bring more favourable results to both 65–80 PPSV–23 strategy and65 PPSV–23 strategy. We
didn’t incorporate the herd effect of PCV–7 or PCV–13 immunisation programmes among
children, which was likely to indirectly protect the elderly and thus potentially reducing the
efficiencies of the immunisation programme using both vaccines. We deferred its incorpo-
ration as it might pose some bias to the result. Though several studies do provide some evi-
dence for the existence of such an effect, further evidence is required before definite
interpretations can be made. The decreasing vaccine-serotype IPD and non-invasive vaccine-
type CAP cases due to serotype replacement during the 15-year cohort time were not incorpo-
rated. The replacement occurred in Japan after the launching of children’s PCV immunisation
programme has decreased the vaccine-serotype IPD among adults from 85% (PPSV–23) and
61% (PCV–7) in 2007 [39] to 60% (PPSV–23) and 40% (PCV–13) in 2013, respectively [19].
The advertising costs borne by manufacturers were left unaccounted. Incorporating these
might bring more unfavourable results.
Several studies have compared the cost-effectiveness of the use of either PPSV–23 or PCV–
13 or substitution of PPSV–23 with PCV–13 among elderly. Different studies has shown that
both PPSV–23 and PCV–13 were cost-effective, and PCV–13 has high value for money than
PPSV–23 [25, 40–44]. ICERs of all three PPSV–23 strategies vs. do-nothing in our study were
too high to conclude that PPSV–23 immunisation programmes for the elderly were cost-effec-
tive (data in S1 Table), which was inconsistent with the results of previous studies. Inconsisten-
cies were due to low incidence rates, low fatality rates, and low proportions of sequelae caused
by S. pneumoniae in our study compared to those in previous studies. All 10 scenarios with dif-
ferent levels of share of PCV–13 have favourable ICERs but were not cost-saving compared to
current strategy, which was inconsistent with the results of previous studies. The inconsistency
observed was due to high vaccination cost.
Regardless of these limitations, we make efforts on literature survey to find out the available
data of epidemiology and prognosis of relevant diseases which were considered to reflect the
current situation of diseases caused by S. pneumoniae in Japan. We believe our results will pro-
vide useful results to policymakers.
Conclusion
Results of our analyses indicate switching the current strategy to65 scenario or including
PCV–13 into the list for single-dose subsidy to the elderly in Japan has value for money. A fur-
ther budget impact analysis is awaited for well-informed policymakers.
Supporting Information
S1 Table. Cost, effectiveness and incremental cost-effectiveness ratio (vs. do-nothing) by
using PPSV–23 only.
(DOCX)
CEA of Pneumococcal Vaccines Immunisation Programme for the Elderly
PLOS ONE | DOI:10.1371/journal.pone.0139140 October 7, 2015 13 / 16
Acknowledgments
This study was supported by research grant for Research on Emerging and Re-emerging Infec-
tious Diseases, Health and Labour Sciences Research Grants from the Ministry of Health,
Labour andWelfare, Japan, and Grant-in-Aid for Scientific Research (C), Japan Society for the
Promotion of Science, The Ministry of Education, Culture, Sports, Science and Technology.
We would like to thank Mr. Xerxes Seposo from the Graduate School of Comprehensive
Human Sciences, University of Tsukuba, for the insightful suggestions with regard to the lan-
guage editing.
Author Contributions
Conceived and designed the experiments: SLHMK IO. Analyzed the data: SLH. Wrote the
paper: SLH.
References
1. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-valent pneu-
mococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged
65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR
Morb Mortal Wkly Rep. 2014; 63:822–5. PMID: 25233284
2. Infectious agents surveillance report (IASR) [Haienkyukin kansensyou 2013 nen genzai]. 2013;34:55–
6. Japanese.
3. Naito T, Matsuda N, Tanei M, Watanabe Y, Watanabe. Relationship between public subsidies and vac-
cination rates with the 23-valent pneumococcal vaccine in elderly persons, including the influence of
the free vaccination campaign after the Great East Japan Earthquake. J Infect Chemother. 2014;
20:450–3. doi: 10.1016/j.jiac.2014.03.004 PMID: 24767466
4. Ministry of Health, Labour andWelfare. Infectious Pneumococcal Disease (among elderly). Japanese.
Available from: http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-
kansenshou/haienkyukin/index_1.html
5. Squires SG, Pelletier L. Publicly-funded influenza and pneumococcal immunization programs in Can-
ada: a progress report. Can Commun Dis Rep. 2000; 26:141–8. PMID: 11008402
6. Public Health England. Pneumococcal Polysaccharide Vaccination (PPV) Uptake. Summary report-
survey year2013. Published April 2014. PHE publications gateway number: 2014042.
7. Australian Government, Department of Health and Ageing. The Australian Immunisation Handbook.
10th edition 2013.
8. Pebody RG, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P. Pneumococcal vaccination pol-
icy in Europe. Euro Surveill. 2005; 10:174–8. PMID: 16280609
9. Samson SI, Mégard Y. Overview of vaccination policies for the elderly in Western European countries.
Aging Clin Exp Res. 2009; 21:210–5. PMID: 19571644
10. Ministry of Internal Affairs and communications. Popultion Estimates (October 2014). Tokyo: Statistics
Bureau: 2015. Japanese.
11. Ministry of Health, Labour andWelfare. Report on Health Center Activities and Health Services for the
Year 2013. Tokyo: Health andWelfare Statistics Association, 2014. Japanese.
12. Infectious Disease Sectional committee of the Tuberculosis and Infectious Disease Control Division of
the MHLW. The Tenth meeting of the committee. July 16th, 2014. Japanese. Available from: http://
www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/
0000058658.pdf.
13. Infectious agents surveillance report (IASR) [Seijin Haienkyuukinnsei Haien no Ekigaku]. 2014 35
(10):238–9. Japanese.
14. Ministry of Health, Labour andWelfare. The 21th life tables. Tokyo: Health andWelfare Statistics
Association; 2015. Japanese.
15. Shiramoto M, Irie S, Juergens C, Yamaji M, Tamai S, Aizawa M, et al. Immunogenicity and safety of 13-
valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged50
years: An open-label trial. Hum Vaccin Immunother. 2014; 10:1850–8. doi: 10.4161/hv.28633 PMID:
25424792
16. Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, et al. Immunogenicity and
safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously
CEA of Pneumococcal Vaccines Immunisation Programme for the Elderly
PLOS ONE | DOI:10.1371/journal.pone.0139140 October 7, 2015 14 / 16
vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013; 31:3585–93. doi: 10.
1016/j.vaccine.2013.05.010 PMID: 23688527
17. Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, et al. Influence of initial vac-
cination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide
vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50
years and older. Vaccine. 2013; 31:3594–602. doi: 10.1016/j.vaccine.2013.04.084 PMID: 23688525
18. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeco-
nomics. 1998; 13:397–409. PMID: 10178664
19. Infectious agents surveillance report (IASR) [Shinsyusei infuruenzakin haienkyukin kansensyou, 2014
nen 8 gatu genzai]. 2014 35(10):229–32. Japanese.
20. Watanabe A, Yanagihara K, Matsumoto T, Kohno S, Aoki N, Oguri T, et al. Nationwide surveillance of
bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Che-
motherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiol-
ogy in 2009: general view of the pathogens' antibacterial susceptibility. J Infect Chemother. 2012;
18:609–20. doi: 10.1007/s10156-012-0434-3 PMID: 22766652
21. Takaki M, Nakama T, Ishida M, Morimoto H, Nagasaki Y, Shiramizu R, et al. High incidence of commu-
nity-acquired pneumonia among rapidly aging population in Japan: a prospective hospital-based sur-
veillance. Jpn J Infect Dis. 2014; 67:269–75. PMID: 25056072
22. Ubukata k. Juusyougata no rensa kyuujinnhaiennkyuukin kannsennsyou ni taisuru sa-berannsu no
koutiku to byouinn kaiseki, sono sinndann tiryou ni kannsuru kennkyuu. Report of Health and Labour
Sciences Research Grants. Tokyo: Ministry of Health, Labour, andWelfare; 2013;1–33. Japanese.
23. Ishida T, Hashimoto T, Arita M, Tojo Y, Tachibana H, Jinnai M. A 3-year prospective study of a urinary
antigen-detection test for Streptococcus pneumoniae in community-acquired pneumonia: utility and
clinical impact on the reported etiology. J Infect Chemother. 2004; 10:359–63. PMID: 15614462
24. Ministry of Health, Labour andWelfare. Vital statistics of Japan 2013. Tokyo: Health andWelfare Sta-
tistics Association; 2014. Japanese.
25. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of
adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal
polysaccharide vaccine. JAMA 2012; 307,804–12. doi: 10.1001/jama.2012.169 PMID: 22357831
26. Medical Economics Division, Health Insurance Bureau, 2013. Iryou kyuhu jitai tyousa, 2013. Tokyo:
Ministry of Health, Labour andWelfare 2013. Japanese.
27. The National Council on Social Security System. Simulation on costs of healthcare and long-term care.
Prime minister of Japan and His Cabinet. Oct 23, 2008. Japanese.
28. National Health Insurance drug price scheme, Japan. 2014. Japanese.
29. Letter from Pfizer Inc. Japan to Ministry of Health, Labour andWelfare: about the price of Prevnar13Ⓡ.
June 24, 2014. Japanese.
30. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in
adults. Cochrane Database of Systematic Reviews 2013, Issue 1: . Art. No.: CD000422. doi: 10.1002/
14651858.CD000422.pub3
31. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate
vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015; 372:1114–25. doi: 10.1056/
NEJMoa1408544 PMID: 25785969
32. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for economic evalua-
tion of health care programmes. 3rd ed. Oxford: Oxford University Press; 2004.
33. Johnson D. The triangular distribution as a proxy for the beta distribution in risk analysis. The Statisti-
cian. 1997; 46:387–98.
34. Stein WE, Keblis MF. A newmethod to simulate the triangular distribution. Mathematical and Computer
Modelling. 2009; 49:1143–7.
35. Borek A, Parlikad AK, Woodall P, Tomasella M. A risk based model for quantifying the impact of infor-
mation quality. Computers in Industry. 2014; 65:354–66.
36. World Health Organization. WHO guide for standardization of economic evaluations of immunization
programmes. WHO Document Production Services: Geneva, Switzerland; 2008.
37. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-
pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ.
2010; 19:422–37. doi: 10.1002/hec.1481 PMID: 19382128
38. Hoshi SL, Kondo M, Okubo I. Cost-effective option in launching a community-based pneumonococcal
vaccination program among the elderly in Japan. Aging Research 2012; 4:e8.
CEA of Pneumococcal Vaccines Immunisation Programme for the Elderly
PLOS ONE | DOI:10.1371/journal.pone.0139140 October 7, 2015 15 / 16
39. Chiba N, Morozumi M, Sunaoshi K, Takahashi S, Takano M, Komori T, et al. Serotype and antibiotic
resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect.
2010; 138:61–8. doi: 10.1017/S0950268809990239 PMID: 19538821
40. Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Cost-effectiveness of pneu-
mococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions.
Vaccine. 2009; 27:4891–904. doi: 10.1016/j.vaccine.2009.05.061 PMID: 19520205
41. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK. Modeling of cost effective-
ness of pneumococcal conjugate vaccination strategies in U.S. older adults. Am J Prev Med. 2013;
44:373–81. doi: 10.1016/j.amepre.2012.11.035 PMID: 23498103
42. Kuhlmann A, Theidel U, Pletz MW, von der Schulenburg JM. Potential cost-effectiveness and benefit-
cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev. 2012; 2:4. doi: 10.1186/
2191-1991-2-4 PMID: 22828176
43. RozenbaumMH, Hak E, van der Werf TS, PostmaMJ. Results of a cohort model analysis of the cost-
effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged >
or = 65 years in the Netherlands. Clin Ther. 2010; 32:1517–32. doi: 10.1016/j.clinthera.2010.06.016
PMID: 20728764
44. Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic
impact of 13-valent pneumococcal conjugate vaccine in US adults aged50 years. Vaccine. 2012;
30:5437–44. doi: 10.1016/j.vaccine.2012.05.076 PMID: 22728289
CEA of Pneumococcal Vaccines Immunisation Programme for the Elderly
PLOS ONE | DOI:10.1371/journal.pone.0139140 October 7, 2015 16 / 16
